Morning Trend | CANSINOBIO continues to decline, when will short-term buying return?

CanSinoBIO (6185.HK) closed lower again on January 30, with occasional tentative buying during the day, but overall fluctuating around the 35 yuan level, lacking the momentum for a sustained rise. The pharmaceutical and innovative drug sectors have recently seen significant adjustments, affected by multiple regulatory pressures and capital withdrawals. CanSino itself has not had any major business updates recently, leading to a cautious and risk-averse market sentiment. Some institutions are attempting to buy at lower prices, but they struggle against overall short-selling pressure, resulting in low trading volumes. Only during short-term overselling do we see small buying orders entering, triggering panic selling with slight volume increases. Sector rebound and intraday capital movements are the only possibilities for future rebounds. From a technical perspective, MACD is weakening, and the K-line is inconsistent throughout the day, with insufficient market sentiment in the main board sector. If it falls below 34.88 yuan in the short term, it may further exacerbate the short-selling advantage. Operational advice: closely monitor intraday movements and sector rebound signals, and control positions until there is a clear return of capital. The overall strategy focuses on right-side following and defensive observation, with timely tracking of medical insurance and policy margins to seize short-term opportunities